Akademik Veri Yönetim Sistemi
Turkish Journal of Internal Medicine, cilt.4, sa.(Supplement 1), ss.160-163, 2022 (Hakemli Dergi)
COVID-19 pneumonia is one of the diseases that can cause hypercoagulability. It is not uncommon
to encounter arterial or venous thromboembolic events during COVID-19 infection. In this case, we
wanted to discuss a case of a pulmonary embolism due to COVID-19 infection, which developed
despite the usage of therapeutic dosage of anticoagulants. A 41-year-old male patient with a known
diabetes mellitus was admitted to our clinic with complaints of cough and headache. The patient was
found to be COVID-19 positive. Along with steroid treatment, 2x6,000 IU enoxaparin treatment was
initiated for the patient. He developed sudden respiratory distress and showed an increase in oxygen
demand. D-dimer value increased abruptly to 35.2 mg/L. Pulmonary CT angiography showed
multiple bilateral subsegmental pulmonary embolisms. Since COVID-19 infection can cause arterial
and venous thromboembolic events in patients following up with COVID-19 pneumonia, prophylactic
anticoagulation should be initiated in hospitalized patients. Attention should be paid to signs of bleeding,
and dose adjustment should be made by monitoring coagulation parameters.